On May 20, 2021, Akeso, Inc. (9926.HK) announced that latest updates on clinical trials of Cadonilimab (PD-1/CTLA-4 bi-specific antibody, AK104), PD-1/VEGF bi-specific antibody ( AK112), CD47 monoclonal antibody ( AK117) and Penpulimab (PD-1 monoclonal antibody, AK105) would be published at the 2021 American Society of Clinical Oncology Annual Meeting ("ASCO 2021").
Summary of the abstracts and electronic posters will be posted on the website of Akeso at http://www.akesobio.com after ASCO 2021
Details of the research are as follows:
Research Title: Phase II study of AK104 (PD-1/CTLA-4 bispecific antibody) plus lenvatinib as first-line treatment of unresectable hepatocellular carcinoma
Abstract Number: 4101
Non-Squamous Non-Small Cell Lung Cancer
Research Title: Penpulimab in combination with anlotinib as first-line treatment in advanced non-squamous non-small cell lung cancer
Abstract Number: e21072
Research Title: A phase II study of Penpulimab, an anti-PD-1 antibody, in patients with relapsed or refractory classic Hodgkin lymphoma (cHL)
Abstract Number: 7529
Research Title: Safety and efficacy of AK112, an anti-PD-1/VEGF-A bispecific antibody, in patients with advanced solid tumors in a phase I dose escalation study
Abstract Number: 2515
Research Title: Safety of AK117, an anti-CD47 monoclonal antibody, in patients with advanced or metastatic solid tumors in a phase I study
Abstract Number: 2630
Small Cell Lung Cancer
Research Title: Penpulimab plus anlotinib as second-line treatment for the small cell lung cancer after failure of platinum-based systemic chemotherapy
Abstract Number: 8568
Research Title: A phase I study of AK119, an anti-CD73 monoclonal antibody, in combination with AK104, an anti-PD-1/CTLA-4 bispecific antibody, in patients with advanced or metastatic solid tumors
Abstract Number: TPS 2675
INFORMATION ABOUT AKESO, Inc.
The Company is a biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of new innovative antibody drugs that are affordable to patients worldwide. Since the Company’s establishment, the Company has established an end-to-end comprehensive drug development platform (ACE Platform) and system, encompassing fully integrated drug discovery and development functions, including target validation, antibody drug discovery and development, CMC production process development, and GMP compliant scale production. The Company has also successfully developed a bi-specific antibody drug development technology (Tetrabody technology). The Company currently has a pipeline of over 20 innovative drugs for the treatment of major diseases like tumors, autoimmune diseases, inflammation and metabolism diseases, 13 of which have entered clinical stage, including two first-in-class bi-specific antibody drugs (PD-1/CTLA-4 and PD-1/VEGF). The Company’s vision is to become a global leading biopharmaceutical company through research and development of high efficacy and breakthrough new drugs that are first-in-class and best-in-class therapies.